GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Thiogenesis Therapeutics TTI.V · CAD

N/A · TSX Venture · 🇨🇦 Canada

Compare

0.64

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Thiogenesis Therapeutics — daily TSXV:TTI Delayed
Market value
C$33.2m
Last close × shares
Volume
25.3k
Shares, 9 Nov 2026

About Thiogenesis Therapeutics

Its shares trade on TSX Venture under the ticker TTI.V. It has been listed since 16 July 2019.

Thiogenesis Therapeutics Corp. engages in developing novel drug formulations that act as precursors for rare diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-16. The firm is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. The company is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the important obstacles facing thiol-based drugs, their short half-life, strong gastrointestinal (GI) side-effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for mitochondrial disease, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).

Figures and description from our data supplier, not checked against the company's own report.

More about Thiogenesis Therapeutics →

Latest on Thiogenesis Therapeutics

Our reporting

We have not reported on Thiogenesis Therapeutics yet.

Next results

26 Nov 2026

Due on 26 Nov 2026.

Other N/A listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Thiogenesis Therapeutics's ticker?

Thiogenesis Therapeutics trades as TTI.V on TSX Venture, under ISIN CA88410L1022.

What was Thiogenesis Therapeutics's last closing price?

0.64 on 9 Nov 2026. The figure is in CAD and is never converted.

When does Thiogenesis Therapeutics next report results?

Results are expected on 26 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.